by Queensland University of Technology QUT pharmaceutical scientist Dr. Nazrul Islam, from School of Clinical Sciences, said lung cancer was one of the most common cancers globally and one of the deadliest, being a leading cause of cancer deaths. He said chitosan had long been investigated for drug delivery and medical applications. It is made from refined crustacean (prawns, crabs, lobster) shells and...
Tag: <span>Lung cancer</span>
Post
Maintenance Immunotherapy fails to improve survival in extensive small cell lung cancer
ELCC 2019 (European Lung Cancer Congress), April 10-13, Geneva, Switzerland EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY Geneva, Switzerland, 11 April 2019 – Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress (ELCC) 2019. (1) Around 60-70% of patients with SCLC have extensive disease at the time of diagnosis, meaning it has spread beyond a...
Post
A new machine learning model can classify lung cancer slides at the pathologist level
Using recent advances in machine learning, a Dartmouth research team has developed a deep neural network to classify different types of a common form of lung cancer on histopathology slides at an accuracy level shown to be on par with pathologists DARTMOUTH-HITCHCOCK MEDICAL CENTER LEBANON, NH – Machine learning has improved dramatically in recent years and shown great...
Post
Raising awareness of lung cancer risk in people with COPD
During this unique study, led by the University of Glasgow and University of Surrey, researchers investigated how the experience of COPD, influences how individuals understand new or changing chest symptoms and their decision to seek help from medical professionals. COPD is the name for a group of lung conditions, including emphysema and chronic bronchitis, which...
Post
Raising awareness of lung cancer risk in people with COPD
People with chronic obstructive pulmonary disease (COPD) need more support when understanding and acting on new chest symptoms, a study in the journal Psycho-Oncologyreports. Credit: CC0 Public Domain During this unique study, led by the University of Glasgow and University of Surrey, researchers investigated how the experience of COPD, influences how individuals understand new or...
Post
First line immunotherapy combination fails to improve overall survival in lung cancer
ESMO Immuno-Oncology Congress, Dec. 13-16, Geneva, Switzerland EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY Geneva, Switzerland, 13 December 2018 – First line Immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology...
Post
Researchers extend effectiveness of immunotherapy to more lung cancer patients
Immunotherapy, the strategy for triggering the patient’s own immune system to attack cancer, is proving effective for more tumour types, although to varying degrees. In lung cancer, immunotherapy had proven to extend survival rates for only some variants of the disease. Now, an international clinical trial led by the oncologist Luis Paz-Ares has substantially increased...
Post
Proposed cancer treatment may boost lung cancer stem cells, study warns
Study adds evidence that cancer stem cells drive adenocarcinoma; suggests new strategy that makes tumor cells less “stem-like” BOSTON CHILDREN’S HOSPITAL Epigenetic therapies — targeting enzymes that alter what genes are turned on or off in a cell — are of growing interest in the cancer field as a way of making a cancer less...
Post
Will tarloxotinib finally break the HER2 barrier in lung cancer?
The HER2 gene is a well-known driver of breast cancer, where changes in this gene are found in about 1-in-5 cases of the disease. HER2 also contributes to about 3 percent of lung cancers, representing about 6,500 patients per year. But while drugs like trastuzumab and lapatinib have proven effective in silencing the action of...
Post
New method uses just a drop of blood to monitor lung cancer treatment
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of which was nivolumab (Opdivo). Nivolumab helps T-cells fight tumors, however, different patients respond in different ways. It now appears...